Published in Arch Neurol on August 01, 2007
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging (2009) 4.36
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol (2009) 2.87
APOE epsilon2 is associated with intact cognition but increased Alzheimer pathology in the oldest old. Neurology (2009) 1.74
Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. Front Genet (2014) 1.56
Gray matter maturation and cognition in children with different APOE ε genotypes. Neurology (2016) 1.42
APOE4-specific changes in Aβ accumulation in a new transgenic mouse model of Alzheimer disease. J Biol Chem (2012) 1.34
The oldest old and the 90+ Study. Alzheimers Dement (2007) 1.02
Interactive effects of apolipoprotein E type 4 genotype and cerebrovascular risk on neuropsychological performance and structural brain changes. J Stroke Cerebrovasc Dis (2010) 1.02
Diagnosing dementia in the oldest-old. Maturitas (2011) 0.93
Brain functional network in Alzheimer's disease: diagnostic markers for diagnosis and monitoring. Int J Alzheimers Dis (2011) 0.91
"End-stage" neurofibrillary tangle pathology in preclinical Alzheimer's disease: fact or fiction? J Alzheimers Dis (2011) 0.90
Apolipoprotein E ε2 and functional decline in amnestic mild cognitive impairment and Alzheimer disease. Am J Geriatr Psychiatry (2012) 0.87
Possible Alzheimer's disease in an apolipoprotein E2 homozygote. J Alzheimers Dis (2009) 0.80
Apolipoprotein E highly correlates with AbetaPP- and tau-related markers in human cerebrospinal fluid. J Alzheimers Dis (2008) 0.80
Neocortical β-amyloid area is associated with dementia and APOE in the oldest-old. Alzheimers Dement (2013) 0.77
Apolipoprotein E ε4 is superior to apolipoprotein E ε2 in predicting cognitive scores over 30 months. Clin Interv Aging (2013) 0.75
Probable early-onset Alzheimer's disease in an apolipoprotein E2 homozygote. Dement Geriatr Cogn Disord (2010) 0.75
Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science (1988) 13.54
Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging (1997) 10.81
Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology (2006) 8.97
Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet (1994) 7.07
Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol (1988) 5.18
Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol (2002) 3.48
Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology (1988) 3.40
Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet (1996) 2.95
Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic study. Arch Neurol (2005) 2.76
Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci U S A (1995) 2.53
Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology (2004) 1.74
Dissociation of neuropathology from severity of dementia in late-onset Alzheimer disease. Neurology (2006) 1.68
Neuropsychological data in nondemented oldest old: the 90+ Study. J Clin Exp Neuropsychol (2007) 1.63
Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription. J Neurochem (2003) 1.51
Prevalence of chronic disease and health practices in a retirement community. J Chronic Dis (1986) 1.51
Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2005) 1.38
Apolipoprotein E-epsilon 2 and Alzheimer's disease: genotype influences pathologic phenotype. Neurology (1997) 1.24
Characterization of the binding of amyloid-beta peptide to cell culture-derived native apolipoprotein E2, E3, and E4 isoforms and to isoforms from human plasma. J Neurochem (1997) 1.20
Frequency of the apolipoprotein E epsilon 2 allele is diminished in sporadic Alzheimer disease. Neurosci Lett (1994) 1.17
Premorbid effects of APOE on synaptic proteins in human temporal neocortex. Neurobiol Aging (2005) 1.13
Apolipoprotein E protects against oxidative stress in mixed neuronal-glial cell cultures by reducing glutamate toxicity. Neurochem Int (2004) 0.99
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science (2003) 18.18
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement (2008) 6.39
Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. Arch Neurol (2003) 4.82
Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener (2007) 4.15
Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease. J Int Neuropsychol Soc (2008) 3.21
Risk factors for mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 2. Arch Neurol (2003) 2.70
Gene expression changes in the course of normal brain aging are sexually dimorphic. Proc Natl Acad Sci U S A (2008) 2.29
Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alpha -lipoic acid. Proc Natl Acad Sci U S A (2002) 2.28
Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis (2009) 2.12
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. J Biol Chem (2008) 2.04
Retracted Human chromosome 21-derived miRNAs are overexpressed in down syndrome brains and hearts. Biochem Biophys Res Commun (2008) 1.91
Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease. Alzheimers Dement (2006) 1.76
APOE epsilon2 is associated with intact cognition but increased Alzheimer pathology in the oldest old. Neurology (2009) 1.74
Survival following a diagnosis of Alzheimer disease. Arch Neurol (2002) 1.69
Neuropsychological data in nondemented oldest old: the 90+ Study. J Clin Exp Neuropsychol (2007) 1.63
Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies. Acta Neuropathol (2011) 1.62
Biliverdin reductase-A: a novel drug target for atorvastatin in a dog pre-clinical model of Alzheimer disease. J Neurochem (2011) 1.53
Retracted Chromosome 21-derived microRNAs provide an etiological basis for aberrant protein expression in human Down syndrome brains. J Biol Chem (2009) 1.53
Caspase-9 activation and caspase cleavage of tau in the Alzheimer's disease brain. Neurobiol Dis (2002) 1.51
Is routine postoperative chest radiography needed after percutaneous nephrolithotomy? Urology (2011) 1.43
Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy. PLoS One (2008) 1.42
Nutrition, brain aging, and neurodegeneration. J Neurosci (2009) 1.40
Brain aging in the canine: a diet enriched in antioxidants reduces cognitive dysfunction. Neurobiol Aging (2002) 1.34
Conformation dependent monoclonal antibodies distinguish different replicating strains or conformers of prefibrillar Aβ oligomers. Mol Neurodegener (2010) 1.34
Size and reversal learning in the beagle dog as a measure of executive function and inhibitory control in aging. Learn Mem (2003) 1.32
The canine (dog) model of human aging and disease: dietary, environmental and immunotherapy approaches. J Alzheimers Dis (2008) 1.31
The A431E mutation in PSEN1 causing familial Alzheimer's disease originating in Jalisco State, Mexico: an additional fifteen families. Neurogenetics (2006) 1.31
Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice. J Neurosci (2007) 1.31
Synaptic proteins, neuropathology and cognitive status in the oldest-old. Neurobiol Aging (2007) 1.28
Alzheimer disease and Down syndrome: factors in pathogenesis. Neurobiol Aging (2005) 1.24
Caspase-mediated cleavage of glial fibrillary acidic protein within degenerating astrocytes of the Alzheimer's disease brain. Am J Pathol (2006) 1.20
Neurogenesis decreases with age in the canine hippocampus and correlates with cognitive function. Neurobiol Learn Mem (2007) 1.19
Locomotor activity rhythms in dogs vary with age and cognitive status. Behav Neurosci (2003) 1.19
Systemic mitochondrial dysfunction and the etiology of Alzheimer's disease and down syndrome dementia. J Alzheimers Dis (2010) 1.19
Lack of pathology in a triple transgenic mouse model of Alzheimer's disease after overexpression of the anti-apoptotic protein Bcl-2. J Neurosci (2008) 1.18
Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and a program of behavioral enrichment: relevance to Alzheimer's disease. Neurobiol Aging (2006) 1.17
The prevalence of disability in the oldest-old is high and continues to increase with age: findings from The 90+ Study. Int J Geriatr Psychiatry (2009) 1.16
Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer's disease. PLoS One (2010) 1.15
Neuropathological heterogeneity in frontotemporal lobar degeneration with TDP-43 proteinopathy: a quantitative study of 94 cases using principal components analysis. J Neural Transm (Vienna) (2009) 1.14
Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene. Eur J Immunol (2003) 1.12
Caspase Activation in the Alzheimer's Disease Brain: Tortuous and Torturous. Drug News Perspect (2002) 1.10
Clinical outcomes of nonoperative management in emphysematous urinary tract infections. Urology (2012) 1.09
ets-2 promotes the activation of a mitochondrial death pathway in Down's syndrome neurons. J Neurosci (2005) 1.09
Frontal cortex neuropathology in dementia pugilistica. J Neurotrauma (2012) 1.08
Down syndrome and dementia: a randomized, controlled trial of antioxidant supplementation. Am J Med Genet A (2011) 1.02
Accumulation of caspase cleaved amyloid precursor protein represents an early neurodegenerative event in aging and in Alzheimer's disease. Neurobiol Dis (2003) 1.02
Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome. Biochim Biophys Acta (2011) 1.02
Region specific neuron loss in the aged canine hippocampus is reduced by enrichment. Neurobiol Aging (2006) 1.01
Frontal lobe volume, function, and beta-amyloid pathology in a canine model of aging. J Neurosci (2004) 1.01
Caspase-cleaved tau accumulation in neurodegenerative diseases associated with tau and alpha-synuclein pathology. Acta Neuropathol (2005) 1.00
Neuroprotective effects of cognitive enrichment. Ageing Res Rev (2006) 1.00
Early brain injury alters the blood-brain barrier phenotype in parallel with β-amyloid and cognitive changes in adulthood. J Cereb Blood Flow Metab (2012) 1.00
Aging and cerebrovascular dysfunction: contribution of hypertension, cerebral amyloid angiopathy, and immunotherapy. Ann N Y Acad Sci (2010) 0.99
BDNF increases with behavioral enrichment and an antioxidant diet in the aged dog. Neurobiol Aging (2010) 0.99
Beta-amyloid, oxidative stress and down syndrome. Curr Alzheimer Res (2006) 0.99
A fibril-specific, conformation-dependent antibody recognizes a subset of Abeta plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain. Acta Neuropathol (2009) 0.98
Caspase activation in Alzheimer's disease: early to rise and late to bed. Rev Neurosci (2008) 0.98
Children of persons with Alzheimer disease: what does the future hold? Alzheimer Dis Assoc Disord (2008) 0.97
Caspases as therapeutic targets in Alzheimer's disease: is it time to "cut" to the chase? Int J Clin Exp Pathol (2008) 0.97
Visuospatial impairments in aged canines (Canis familiaris): the role of cognitive-behavioral flexibility. Behav Neurosci (2002) 0.96
Caspase-cleaved amyloid precursor protein and activated caspase-3 are co-localized in the granules of granulovacuolar degeneration in Alzheimer's disease and Down's syndrome brain. Acta Neuropathol (2002) 0.96
Atorvastatin treatment in a dog preclinical model of Alzheimer's disease leads to up-regulation of haem oxygenase-1 and is associated with reduced oxidative stress in brain. Int J Neuropsychopharmacol (2011) 0.96
PET imaging predicts future body weight and cocaine preference. Neuroimage (2011) 0.95
BACE2 expression increases in human neurodegenerative disease. Am J Pathol (2011) 0.95
Isolated executive impairment and associated frontal neuropathology. Dement Geriatr Cogn Disord (2004) 0.94
Bapineuzumab alters aβ composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy. PLoS One (2013) 0.94
Advancing Alzheimer's disease diagnosis, treatment, and care: recommendations from the Ware Invitational Summit. Alzheimers Dement (2012) 0.94
Visuospatial function in the beagle dog: an early marker of cognitive decline in a model of human aging and dementia. Neurobiol Learn Mem (2006) 0.94
Application of an automated voxel-based morphometry technique to assess regional gray and white matter brain atrophy in a canine model of aging. Neuroimage (2005) 0.93
BioVision: an application for the automated image analysis of histological sections. Neurobiol Aging (2005) 0.92
Learning and memory as a function of age in Down syndrome: a study using animal-based tasks. Prog Neuropsychopharmacol Biol Psychiatry (2005) 0.92
Protective effects of R-alpha-lipoic acid and acetyl-L-carnitine in MIN6 and isolated rat islet cells chronically exposed to oleic acid. J Cell Biochem (2008) 0.91
Elevated stearoyl-CoA desaturase in brains of patients with Alzheimer's disease. PLoS One (2011) 0.90
Long-term treatment with antioxidants and a program of behavioral enrichment reduces age-dependent impairment in discrimination and reversal learning in beagle dogs. Exp Gerontol (2004) 0.90
Session II: Mechanisms of age-related cognitive change and targets for intervention: neural circuits, networks, and plasticity. J Gerontol A Biol Sci Med Sci (2012) 0.90
Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: a novel mechanism of action. Pharmacol Res (2010) 0.90
Comparison of the effects of L-carnitine and acetyl-L-carnitine on carnitine levels, ambulatory activity, and oxidative stress biomarkers in the brain of old rats. Ann N Y Acad Sci (2004) 0.89
Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer's disease neuropathology: redox proteomics analysis of human brain. Biochim Biophys Acta (2013) 0.89
Mapping brain metabolic connectivity in awake rats with μPET and optogenetic stimulation. J Neurosci (2013) 0.88
An amyloid β42-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimer's disease. Neurobiol Aging (2011) 0.88
Synergistic effects of long-term antioxidant diet and behavioral enrichment on beta-amyloid load and non-amyloidogenic processing in aged canines. J Neurosci (2010) 0.87
Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels as a central target for the development of human AD and AD-like pathology in aged transgenic mice. Ann N Y Acad Sci (2002) 0.87
Chronic antioxidant and mitochondrial cofactor administration improves discrimination learning in aged but not young dogs. Prog Neuropsychopharmacol Biol Psychiatry (2005) 0.86
Obesity-resistant S5B rats showed greater cocaine conditioned place preference than the obesity-prone OM rats. Physiol Behav (2010) 0.86
Changes in cognition and amyloid-β processing with long term cholesterol reduction using atorvastatin in aged dogs. J Alzheimers Dis (2010) 0.86
A comparison of egocentric and allocentric age-dependent spatial learning in the beagle dog. Prog Neuropsychopharmacol Biol Psychiatry (2005) 0.84
Is Apolipoprotein E4 an Important Risk Factor for Dementia in Persons with Down Syndrome? J Parkinsons Dis Alzheimers Dis (2014) 0.84
Using U.S. Medicare records to evaluate the indirect health effects on spouses: a case study in Alzheimer's disease patients. BMC Health Serv Res (2014) 0.84
Rarity of the Alzheimer disease-protective APP A673T variant in the United States. JAMA Neurol (2015) 0.84
Longitudinal medication usage in Alzheimer disease patients. Alzheimer Dis Assoc Disord (2014) 0.84